BR0009170A - ácidos nucléicos akt, polipeptìdeos e uso dos mesmos - Google Patents

ácidos nucléicos akt, polipeptìdeos e uso dos mesmos

Info

Publication number
BR0009170A
BR0009170A BR0009170-7A BR0009170A BR0009170A BR 0009170 A BR0009170 A BR 0009170A BR 0009170 A BR0009170 A BR 0009170A BR 0009170 A BR0009170 A BR 0009170A
Authority
BR
Brazil
Prior art keywords
polypeptides
nucleic acids
akt3
akt nucleic
relates
Prior art date
Application number
BR0009170-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Kun Guo
Marco Pagnoni
Kenneth L Clark
Yuri D Ivashchenko
Original Assignee
Aventis Pharm Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharm Prod Inc filed Critical Aventis Pharm Prod Inc
Publication of BR0009170A publication Critical patent/BR0009170A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
BR0009170-7A 1999-03-19 2000-03-14 ácidos nucléicos akt, polipeptìdeos e uso dos mesmos BR0009170A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12510899P 1999-03-19 1999-03-19
PCT/US2000/006574 WO2000056866A2 (en) 1999-03-19 2000-03-14 Akt-3 nucleic acids, polypeptides, and uses thereof

Publications (1)

Publication Number Publication Date
BR0009170A true BR0009170A (pt) 2002-04-30

Family

ID=22418217

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0009170-7A BR0009170A (pt) 1999-03-19 2000-03-14 ácidos nucléicos akt, polipeptìdeos e uso dos mesmos

Country Status (18)

Country Link
EP (1) EP1144600B1 (enExample)
JP (1) JP4237945B2 (enExample)
KR (1) KR100700908B1 (enExample)
AT (1) ATE402995T1 (enExample)
AU (1) AU782448B2 (enExample)
BR (1) BR0009170A (enExample)
CA (1) CA2343074C (enExample)
CY (1) CY1108459T1 (enExample)
DE (1) DE60039677D1 (enExample)
DK (1) DK1144600T3 (enExample)
ES (1) ES2310515T3 (enExample)
HK (1) HK1041288B (enExample)
IL (4) IL141984A0 (enExample)
NO (1) NO20014537L (enExample)
PT (1) PT1144600E (enExample)
SI (1) SI1144600T1 (enExample)
WO (1) WO2000056866A2 (enExample)
ZA (1) ZA200108414B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6881555B2 (en) 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
WO2000062605A1 (en) 1999-04-16 2000-10-26 Yale University eNOS MUTATIONS USEFUL FOR GENE THERAPY AND THERAPEUTIC SCREENING
WO2000077190A2 (en) * 1999-06-11 2000-12-21 Aventis Pharmaceuticals Products Inc. Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt
JPWO2003063905A1 (ja) * 2002-01-31 2005-05-26 株式会社東京大学Ｔｌｏ 免疫疾患の予防又は治療剤
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
EP1661581A1 (en) * 2003-07-28 2006-05-31 Osaka Industrial Promotion Organization Remedy for cardiac failure comprising ask1 inhibitor as the active ingredient and method of screening the same
EP2599793A1 (en) * 2008-05-29 2013-06-05 Nuclea Biotechnologies, Inc. Anti-phospho-akt antibodies
TWI491606B (zh) 2009-07-13 2015-07-11 Gilead Sciences Inc 調節細胞凋亡信號之激酶的抑制劑
CN102985418B (zh) 2010-07-02 2015-09-09 吉利德科学股份有限公司 凋亡信号调节激酶抑制剂
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
ES2731602T3 (es) 2014-09-24 2019-11-18 Gilead Sciences Inc Métodos para tratar la enfermedad hepática
CA3100432C (en) 2014-12-23 2023-08-08 Gilead Sciences, Inc. Processes for preparing ask1 inhibitors
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
WO2020180886A1 (en) * 2019-03-04 2020-09-10 The Trustees Of The University Of Pennsylvania Neuroprotective gene therapy targeting the akt pathway

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08109197A (ja) * 1994-10-07 1996-04-30 Sumitomo Electric Ind Ltd 白血病腫瘍拒絶抗原ペプチド
DE69633186T2 (de) * 1995-11-16 2005-08-18 Novartis Ag Methode zur Identifizierung von Verbindungen die mit RAC Proteine Kinase interagieren
US5958773A (en) * 1998-12-17 1999-09-28 Isis Pharmaceuticals Inc. Antisense modulation of AKT-1 expression
GB9828375D0 (en) * 1998-12-22 1999-02-17 Janssen Pharmaceutica Nv Human akt-3
US6043090A (en) * 1999-03-23 2000-03-28 Isis Pharmaceuticals Inc. Antisense inhibition of human Akt-2 expression
CA2383592A1 (en) * 1999-03-31 2000-10-05 Curagen Corporation 2384891 acids including open reading frames encoding polypeptides; orfx
WO2000077190A2 (en) * 1999-06-11 2000-12-21 Aventis Pharmaceuticals Products Inc. Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt

Also Published As

Publication number Publication date
EP1144600B1 (en) 2008-07-30
NO20014537D0 (no) 2001-09-18
DK1144600T3 (da) 2008-11-24
AU3880200A (en) 2000-10-09
DE60039677D1 (de) 2008-09-11
ATE402995T1 (de) 2008-08-15
PT1144600E (pt) 2008-10-10
WO2000056866A2 (en) 2000-09-28
CY1108459T1 (el) 2013-09-04
WO2000056866A9 (en) 2002-08-29
EP1144600A2 (en) 2001-10-17
SI1144600T1 (sl) 2008-12-31
IL141984A0 (en) 2002-03-10
AU782448B2 (en) 2005-07-28
IL145514A0 (en) 2002-06-30
HK1041288B (en) 2008-11-07
NO20014537L (no) 2001-10-31
JP2002539781A (ja) 2002-11-26
CA2343074C (en) 2010-09-21
WO2000056866A3 (en) 2001-02-15
KR20020011972A (ko) 2002-02-09
ZA200108414B (en) 2003-03-26
KR100700908B1 (ko) 2007-03-29
CA2343074A1 (en) 2000-09-28
JP4237945B2 (ja) 2009-03-11
HK1041288A1 (en) 2002-07-05
IL145514A (en) 2010-05-17
ES2310515T3 (es) 2009-01-16
IL190270A (en) 2012-12-31

Similar Documents

Publication Publication Date Title
CY1108459T1 (el) Ακτ-3 νουκλεϊκα οξεα, πολυπεπτιδια, και χρησεις αυτων
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
AU3000297A (en) Use of protein kinase c inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
DE69435307D1 (de) Bazillus Thuringiensis und dessen insektizide Proteine
ATE294236T1 (de) Promotor der tie rezeptor protein kinase
DK1255845T3 (da) Modificerede cytokiner til anvendelse i cancerterapi
ATE531789T1 (de) Zellmembranenveränderung
WO2001034641A3 (en) Antimicrobial activity of the first cationic cluster of human lactoferrin
BR0212070A (pt) ácidos nucléicos e polipeptìdeos bv8 com atividade mitogênica
EE200000102A (et) Meetodid ja kompositsioonid teraapiaks, kasutades sekreteeritavaid valke, näiteks interferoon-beetat kodeerivaid geene
PT1140023E (pt) Formulacoes cocleares integrativas de proteina-adn e metodos de transformacao celular
ATE302215T1 (de) Modulatoren von intrazellulären entzündungs-, zelltod- und zellüberlebenswegen, die card- und kinase-domänen enthalten
WO2002014369A3 (en) Human kininogen d5 domain polypeptides and their use
AU1141695A (en) Interferon-alpha/beta binding protein, its preparation and use
DE60008077D1 (de) Matrixprotein zusammensetzungen um apoptose zu induzieren
HUP0300813A2 (hu) Gének, fehérjék és alkalmazásuk
ATE466588T1 (de) Bakteriophagen- und prophagen-proteine in der krebsgentherapie
PT980379E (pt) Oligonucleotidos quimericos e sua utilizacao
GB9723824D0 (en) Cytostatic agents
NZ506005A (en) Recombinant proteins derived from hgf and msp
CY1113344T1 (el) Χρηση της il-21 στον καρκινο και μονοκλωνικα αντισωματα για θεραπευτικη αγωγη στερεων καρκινων
WO2002006340A3 (en) Tetraspan protein and uses thereof
HK1019854A (en) Use of protein kinase c inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 25, 10(VIII), 10(X), 13 E 8O DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.